Phaseline

Companies › Mahzi Therapeutics

Mahzi Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Mar 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MZ-1866
AAV-9 gene therapy for TCF4 gene replacement
TCF4Phase 1Pitt Hopkins SyndromeMar 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07135050MZ-1866Phase 1Pitt Hopkins SyndromeOtherMar 2029

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

TCF4 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.